Drug-related problems in older patients with advanced chronic kidney disease identified during pretransplant comprehensive geriatric assessment.


Journal

Nephrologie & therapeutique
ISSN: 1872-9177
Titre abrégé: Nephrol Ther
Pays: France
ID NLM: 101248950

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 06 01 2021
revised: 26 07 2021
accepted: 17 08 2021
pubmed: 11 11 2021
medline: 11 2 2022
entrez: 10 11 2021
Statut: ppublish

Résumé

Older patients with advanced chronic kidney disease may be exposed to a higher risk of adverse drug events due to chronic kidney disease and aging. The integration of clinical pharmacist into pretransplant comprehensive geriatric assessment is an opportunity to perform medication optimization. The aim was to describe drug-related problems in older patients with advanced chronic kidney disease. Observational study was conducted with retrospective data from July 2017 to April 2019. Patients≥65 years with advanced chronic kidney disease, referred by nephrologists for pretransplant comprehensive geriatric assessment were included. During medication optimization, the pharmacist evaluated the appropriateness of each medication prescribed and identified drug-related problems. Any drug-related problem identified lead to a pharmaceutical intervention. In total, 103 patients were included (74.5±2.9 years, 26.2% female, 47.6% on dialysis). Overall, 394 drug-related problems were identified in 93.2% of patients (3.8±2.4 drug-related problems per patient) during the medication optimization. Cardiovascular medications (25.1%), antithrombotics (13.5%) and drugs for peptic ulcer and reflux disease (10.2%) were the most involved drugs in drug-related problems. Drug-related problems mainly concerned drugs without indication (27.1%), inappropriate method of administration (24.4%) and non-conformity to guidelines (20.1%). A high prevalence of drug-related problems in older patients with advanced chronic kidney disease was identified during medication optimization. The systematic integration of a clinical pharmacist in the multidisciplinary team performing pretransplant comprehensive geriatric assessment may be relevant to detect inappropriate prescriptions and to prevent from adverse drug events.

Sections du résumé

BACKGROUND BACKGROUND
Older patients with advanced chronic kidney disease may be exposed to a higher risk of adverse drug events due to chronic kidney disease and aging. The integration of clinical pharmacist into pretransplant comprehensive geriatric assessment is an opportunity to perform medication optimization.
OBJECTIVE OBJECTIVE
The aim was to describe drug-related problems in older patients with advanced chronic kidney disease.
METHODS METHODS
Observational study was conducted with retrospective data from July 2017 to April 2019. Patients≥65 years with advanced chronic kidney disease, referred by nephrologists for pretransplant comprehensive geriatric assessment were included. During medication optimization, the pharmacist evaluated the appropriateness of each medication prescribed and identified drug-related problems. Any drug-related problem identified lead to a pharmaceutical intervention.
RESULTS RESULTS
In total, 103 patients were included (74.5±2.9 years, 26.2% female, 47.6% on dialysis). Overall, 394 drug-related problems were identified in 93.2% of patients (3.8±2.4 drug-related problems per patient) during the medication optimization. Cardiovascular medications (25.1%), antithrombotics (13.5%) and drugs for peptic ulcer and reflux disease (10.2%) were the most involved drugs in drug-related problems. Drug-related problems mainly concerned drugs without indication (27.1%), inappropriate method of administration (24.4%) and non-conformity to guidelines (20.1%).
CONCLUSION CONCLUSIONS
A high prevalence of drug-related problems in older patients with advanced chronic kidney disease was identified during medication optimization. The systematic integration of a clinical pharmacist in the multidisciplinary team performing pretransplant comprehensive geriatric assessment may be relevant to detect inappropriate prescriptions and to prevent from adverse drug events.

Identifiants

pubmed: 34756826
pii: S1769-7255(21)00532-0
doi: 10.1016/j.nephro.2021.08.006
pii:
doi:

Substances chimiques

Pharmaceutical Preparations 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

45-51

Informations de copyright

Copyright © 2021 Société francophone de néphrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Marie-Anne Cerfon (MA)

Pharmaceutical Unit, Charpennes Hospital, University Hospital of Lyon, 69100 Villeurbanne, France.

Julien Vernaudon (J)

Day-care unit, Charpennes Hospital, University Hospital of Lyon, 69100 Villeurbanne, France.

Frédéric Gervais (F)

Pharmaceutical Unit, Charpennes Hospital, University Hospital of Lyon, 69100 Villeurbanne, France.

Emmanuel Morelon (E)

Department of transplantation, nephrology and clinical immunology, Edouard-Herriot Hospital, University Hospital of Lyon, 69003 Lyon, France; University Lyon 1, 69008 Lyon, France.

Marie-Hélène Coste (MH)

Day-care unit, Charpennes Hospital, University Hospital of Lyon, 69100 Villeurbanne, France.

Pierre Krolak-Salmon (P)

Day-care unit, Charpennes Hospital, University Hospital of Lyon, 69100 Villeurbanne, France; University Lyon 1, 69008 Lyon, France; Inserm U1028, CNRS UMR5292; Lyon neuroscience research center, brain dynamics and cognition team, 69675 Bron, France.

Christelle Mouchoux (C)

Pharmaceutical Unit, Charpennes Hospital, University Hospital of Lyon, 69100 Villeurbanne, France; University Lyon 1, 69008 Lyon, France; Inserm U1028, CNRS UMR5292; Lyon neuroscience research center, brain dynamics and cognition team, 69675 Bron, France.

Teddy Novais (T)

Pharmaceutical Unit, Charpennes Hospital, University Hospital of Lyon, 69100 Villeurbanne, France; University Lyon 1, 69008 Lyon, France; Inserm U1290, Research on Healthcare Performance (RESHAPE), University Lyon 1, 69008. Lyon, France. Electronic address: teddy.novais@chu-lyon.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH